6 active not recruiting. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 6 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Electrocardiogram: new trials by email Literature Review of Electrocardiogram trials Research Report on Electrocardiogram
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 78 | 2024-01-08 | 2026-08-25 |
| Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency Mycophenolate Mofetil, Tacrolimus, Post-Transplant Cyclophosphamide - GATA2, Immunodeficiency | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2023-11-29 | 2026-08-11 |
| Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer PRGN-2009, Pembrolizumab, EKG - Oropharyngeal Squamous Cell Carcinoma (SCC) | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 26 | 2023-11-07 | 2026-06-23 |
| Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation e-ATG, Immunosuppression Only Conditioning, Reduced Intensity Conditioning - Lymphoproliferative Disorders, Autoimmune Lymphoproliferative | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 71 | 2018-09-04 | 2026-03-17 |
| Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Lenalidomide, Rituximab, Prednisone - Primary Effusion Lymphoma, B-Cell Neoplasm | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2017-07-03 | 2026-10-20 |
| Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia Cladribine, Rituximab, BMbx - Hairy Cell Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 175 | 2008-10-20 | 2026-08-18 |
Autoimmune Diseases (1) · Common Variable Immunodeficiency (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Hairy Cell (1) · Lymphoma, AIDS-Related (1) · Lymphoma, B-Cell (1) · Lymphoma, Primary Effusion (1) · Lymphoproliferative Disorders (1) · Neoplasm, Residual (1) · Opportunistic Infections (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
National Cancer Institute (NCI) (5) · Children's Oncology Group (1)
United States (6) · Canada (1)
Charalampos Floudas, M.D. (1) · Danielle E Pregent-Arnold, M.D. (1) · Dimana Dimitrova, M.D. (1) · Kelly E Faulk (1) · Ramya Ramaswami, MBBS, MPH (1) · Robert J Kreitman, M.D. (1)
U10CA180886 (1)